Therapeutic Opportunities To Target Tumor Initiating Cells in Solid Tumors

• Post author:
• Post published:February 27, 2026
• Post category:

Cancer is a major cause of human death worldwide. The vast majority of cancer patients suffer from solid tumors whose growth destroys vital organs. We propose to develop novel therapeutic…

Continue ReadingTherapeutic Opportunities To Target Tumor Initiating Cells in Solid Tumors

A Phase 1 trial of RNDP-001, a dopaminergic progenitor drug product, in idiopathic Parkinson’s Disease

• Post author:
• Post published:February 26, 2026
• Post category:

Continue ReadingA Phase 1 trial of RNDP-001, a dopaminergic progenitor drug product, in idiopathic Parkinson’s Disease

Phase I/II Clinical Trial for CMT4J

• Post author:
• Post published:February 26, 2026
• Post category:

Continue ReadingPhase I/II Clinical Trial for CMT4J

Clinical Development of ETX101, a Gene Regulation Therapy for SCN1A+ Dravet Syndrome

• Post author:
• Post published:February 26, 2026
• Post category:

Continue ReadingClinical Development of ETX101, a Gene Regulation Therapy for SCN1A+ Dravet Syndrome

Phase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD)

• Post author:
• Post published:February 26, 2026
• Post category:

Continue ReadingPhase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD)

Optogenetic Gene Therapy for Treatment of Retinitis Pigmentosa

• Post author:
• Post published:February 26, 2026
• Post category:

Continue ReadingOptogenetic Gene Therapy for Treatment of Retinitis Pigmentosa

Inhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy

• Post author:
• Post published:February 26, 2026
• Post category:

Continue ReadingInhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy

TRX103 for prevention of GvHD in patients receiving HLA mismatched HSCT for the treatment of hematologic malignancies

• Post author:
• Post published:February 26, 2026
• Post category:

Continue ReadingTRX103 for prevention of GvHD in patients receiving HLA mismatched HSCT for the treatment of hematologic malignancies

Phase 1b Study of TN-401 in Adults with PKP2 Mutation-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

• Post author:
• Post published:February 26, 2026
• Post category:

Continue ReadingPhase 1b Study of TN-401 in Adults with PKP2 Mutation-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

The UCLA Delayed Immunological Tolerance after Kidney Transplantation Program

• Post author:
• Post published:February 26, 2026
• Post category:

Continue ReadingThe UCLA Delayed Immunological Tolerance after Kidney Transplantation Program